---
title: "Canaccord Genuity Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293435546.md"
description: "Canaccord Genuity analyst Shane Storey maintained a Buy rating on Resmed Inc CHESS Depositary Interests (RMD) with a price target of A$40.00, while shares closed at A$27.94. This follows a Buy from UBS's Marcus Curley and contrasts with Morgan Stanley's Hold rating. Storey covers the Healthcare sector and has a 46.08% success rate on recommendations."
datetime: "2026-07-22T06:57:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293435546.md)
  - [en](https://longbridge.com/en/news/293435546.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293435546.md)
---

# Canaccord Genuity Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)

In a report released yesterday, Shane Storey from Canaccord Genuity maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, with a price target of A$40.00. The company’s shares closed today at A$27.94.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Storey covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, and Aroa Biosurgery Ltd. According to TipRanks, Storey has an average return of 1.3% and a 46.08% success rate on recommended stocks.

In addition to Canaccord Genuity, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh also received a Buy from UBS’s Marcus Curley in a report issued on July 20. However, on July 15, Morgan Stanley maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (ASX: RMD).

### Related Stocks

- [RMD.US](https://longbridge.com/en/quote/RMD.US.md)
- [RMD.AU](https://longbridge.com/en/quote/RMD.AU.md)
- [TLX.AU](https://longbridge.com/en/quote/TLX.AU.md)
- [TLX.US](https://longbridge.com/en/quote/TLX.US.md)
- [ARX.AU](https://longbridge.com/en/quote/ARX.AU.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [16:40 ETBetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)](https://longbridge.com/en/news/293384376.md)
- [How Investors Are Reacting To ResMed (RMD) Downgrade Amid FY27 Cost and Supply Pressures](https://longbridge.com/en/news/293088548.md)
- [Ord Minnett Reaffirms Their Hold Rating on Lotus Resources Limited (LOT)](https://longbridge.com/en/news/293860786.md)
- [RBC Capital Sticks to Their Hold Rating for Beach Energy  (BEPTF)](https://longbridge.com/en/news/293692294.md)
- [Jarden Reaffirms Their Sell Rating on Syrah Resources (SYAAF)](https://longbridge.com/en/news/293857818.md)